Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Elevance Health (ELV) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareELV

Closing price · Nov 19, 2026 $391.13 -2.4% on the day · +26.1% over 12 months 52-week range $276.69 – $446.28
Get ELV alerts
Open-market purchases3 insiders$2.6M · last 12 months
Insiders selling6last 12 months
Reported sales$7.0M0 of 19 recent sales pre-planned (10b5-1)
In 15 seconds

Some insider buying ($2.6M), but sales were much larger ($7.0M) over the same 12 months.

Past insider buys here: 3 of 3 beat the S&P 500 over the next 90 days (small sample). See each one ↓

Label: Mixed: buying, heavier selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
  • 90-day result for Ramiro G. Peru's $384K buy: in on Feb 18, 2027. See the 7- and 30-day results ↓
  • Next earnings expected around Jan 27, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Latest open-market trade

Purchase Ramiro G. Peru, Director bought 1,000 shares at $383.86 ($384K).

Trade date
Nov 19, 2026
Disclosed to the SEC
Nov 20, 2026
Type
Open-market purchase (code P)

Read the original SEC filing ↗All ELV insider trades ↓

✦ Read the full investigation of Ramiro G. Peru's $384K buy (Nov 20) →

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

ELV insider transactions (Form 4)

Open-market purchases and sales. 52 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Nov 20 NewSEC Ramiro G. PeruDirector Buy 1,00011,908 held (+9%) $383.86 $384K — —
Nov 6SEC Ratnakar LavuEvp & Chief Digital Info Ofr Sell 1,30014,849 held (−8%) $440.00 $572K -11.1% —
Oct 23SEC Mark KayeCFO Sell 2,34322,099 held (−10%) $441.34 $1.0M -11.4% —
Oct 23SEC Mark KayeCFO Sell 1,72024,442 held (−7%) $440.44 $758K -11.2% —
Oct 23SEC Mark KayeCFO Sell 1,66028,122 held (−6%) $436.20 $724K -10.3% —
Oct 23SEC Mark KayeCFO Sell 1,16026,162 held (−4%) $439.25 $510K -11.0% —
Oct 23SEC Mark KayeCFO Sell 82720,192 held (−4%) $446.05 $369K -12.3% —
Oct 23SEC Mark KayeCFO Sell 56027,562 held (−2%) $437.07 $245K -10.5% —
Oct 23SEC Mark KayeCFO Sell 48021,619 held (−2%) $442.61 $212K -11.6% —
Oct 23SEC Mark KayeCFO Sell 44021,179 held (−2%) $443.81 $195K -11.9% —
Oct 23SEC Mark KayeCFO Sell 40030,103 held (−1%) $434.00 $174K -9.9% —
Oct 23SEC Mark KayeCFO Sell 32129,782 held (−1%) $435.25 $140K -10.1% —
Oct 23SEC Mark KayeCFO Sell 27319,919 held (−1%) $447.19 $122K -12.5% —
Oct 23SEC Mark KayeCFO Sell 24027,322 held (−1%) $438.22 $105K -10.7% —
Oct 23SEC Mark KayeCFO Sell 16021,019 held (−1%) $444.85 $71K -12.1% —
Jul 17SEC Gail BoudreauxCEO, President Buy 2,045171,976 held (+1%) $368.25 $753K +6.2% —
Jul 17SEC Ramiro G. PeruDirectorFirst buy Buy 1,00010,908 held (+10%) $366.05 $366K +6.9% —
Jul 17SEC Gail BoudreauxCEO, President Buy 680169,931 held (+0%) $366.41 $249K +6.7% —
Jun 15SEC Ronald W. PenczekCao & Controller Sell 3693,740 held (−9%) $403.16 $149K -3.0% —
Jun 12SEC Robert L. Dixon Jr.Director Sell 15110,734 held (−1%) $401.77 $61K -2.6% —
May 20SEC Ronald W. PenczekCao & Controller Sell 1,5314,109 held (−27%) $403.13 $617K -3.0% —
Mar 23SEC Amy W. SchulmanDirector Sell 26218 held (−11%) $287.50 $7K +36.0% —
Mar 9SEC Charles Morgan Kendrick Jr.President Sell 3,19611,791 held (−21%) $284.92 $911K +37.3% —
Mar 6SEC Steven H. CollisDirectorFirst buyStake +469% Buy 3,0003,639 held (+469%) $289.84 $870K +34.9% 54

Play with ELV in the Research Lab

Pre-set to ELV's latest insider buy of $10K or more (Nov 20, 2026: Ramiro G. Peru, $384K). Tap to change anything.

All tools →

Share price and insider trades

ELV closeInsider buyInsider sale
250300350400450DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-01-28EEarnings release filed 2026-04-22EEarnings release filed 2026-07-15EEarnings release filed 2026-10-21Sold $7,475 on 2026-03-12 · Amy W. SchulmanSold $60,667 on 2026-06-11 · Robert L. Dixon Jr.Sold $148,766 on 2026-06-12 · Ronald W. PenczekBought $383,860 on 2026-11-19 · Ramiro G. PeruSold $572,000 on 2026-11-05 · Ratnakar LavuSold $617,192 on 2026-05-19 · Ronald W. PenczekBought $869,520 on 2026-03-05 · Steven H. CollisSold $910,604 on 2026-03-06 · Charles Morgan Kendrick Jr.Bought $1,368,280 on 2026-07-17 · Gail Boudreaux, Ramiro G. PeruSold $4,658,357 on 2026-10-22 · Mark Kaye
Bought, 12 months$2.6M
Sold, 12 months$7.0M
Insiders buying3
Insiders selling6

Elevance Health insider trading at a glance (Nov 20, 2026): in the past 12 months, 3 insiders bought $2.6M and 6 sold $7.0M of ELV stock on the open market; P/E 14.9 vs. a sector median of 25.0.

Setup Odds: how past setups like this did

ELV's latest insider buying (Nov 20, 2026) matched against every similar buy since 2020.

How it works →

1 insider buying no CEO or CFO $250K–$1M stock down 0–20% in 3 months

111 of 221 past setups like this beat the S&P 500 over the next 90 days (50%), against 46% for all insider buys.

50 of 100 similar setups beat the S&P 500beat didn't
−40%−20%0% = S&P+20%+40%
How those 221 cases did vs. the S&P 500 over 90 days. Hover a bar for counts.
Outcome Cloud each dot is one of these 221 past setups; the white ring is ELV's buy, result due in 90 days
Beat the S&P 500 ↑Lagged ↓-50%-25%+0%+25%+50%2020202120222023202420252026BDC 2022-06-21: +31% vs S&P +4%BHVN 2026-03-09: +6% vs S&P +9%ASPN 2023-09-07: +84% vs S&P +3%ADSK 2025-03-24: +10% vs S&P +4%BSM 2026-05-14: +7% vs S&P +4%ASMB 2024-01-19: +29% vs S&P +4%ADP 2026-05-11: +29% vs S&P +5%COLD 2020-12-10: +3% vs S&P +7%OPBK 2022-12-15: -19% vs S&P +0%WY 2022-06-09: -10% vs S&P -0%ACRE 2022-02-25: +5% vs S&P -7%CROX 2024-10-30: -5% vs S&P +5%BMRN 2022-11-02: +37% vs S&P +9%ARKR 2022-12-22: +9% vs S&P +3%ACGL 2026-05-04: +7% vs S&P +4%BRK-B 2026-05-06: +10% vs S&P +5%CODI 2020-06-04: +5% vs S&P +15%CLAR 2024-11-14: +11% vs S&P +2%MBC 2024-08-13: +17% vs S&P +11%BXP 2020-03-12: -10% vs S&P +29%BBW 2022-03-21: +1% vs S&P -17%BXP 2023-03-15: +2% vs S&P +13%TREIX 2023-01-05: +2% vs S&P +8%ADBE 2022-01-10: -15% vs S&P -4%ALLE 2025-11-25: -4% vs S&P +1%COLB 2021-11-29: +13% vs S&P -5%AASP 2026-04-29: +40% vs S&P +4%CE 2022-02-28: +15% vs S&P -5%CME 2024-01-19: +4% vs S&P +4%CME 2020-06-12: -6% vs S&P +10%MBUU 2024-02-23: -16% vs S&P +4%AUR 2025-08-07: -28% vs S&P +7%BX 2022-04-28: -9% vs S&P -6%CDW 2023-05-04: +21% vs S&P +12%BANF 2021-09-14: +23% vs S&P +5%CAI 2026-07-13: +74% vs S&P +4%AFG 2025-02-24: +3% vs S&P -3%CLMT 2023-11-21: +10% vs S&P +11%ATRA 2021-06-15: +15% vs S&P +6%OPBK 2022-08-31: -3% vs S&P +0%AJG 2025-11-03: +3% vs S&P +2%BRO 2023-03-17: +23% vs S&P +13%ALLE 2026-03-12: -11% vs S&P +9%ONEW 2026-02-13: -6% vs S&P +10%BUR 2025-03-10: +4% vs S&P +7%ALKS 2022-11-16: +24% vs S&P +5%CBSH 2022-06-13: +9% vs S&P +9%BHM 2023-03-14: -16% vs S&P +11%CLFD 2025-12-15: -2% vs S&P -2%AGCO 2025-05-07: +21% vs S&P +12%BETA 2026-05-21: +65% vs S&P +4%CDZI 2026-05-28: -8% vs S&P +2%CFR 2022-05-04: -5% vs S&P -4%AESI 2024-10-28: +21% vs S&P +5%OPBK 2022-03-08: -6% vs S&P -1%BPRN 2024-03-18: +3% vs S&P +6%CAG 2021-01-11: +10% vs S&P +9%AMD 2025-02-12: +1% vs S&P -2%COST 2022-06-08: +11% vs S&P -5%DAL 2024-07-15: +20% vs S&P +4%BSTZ 2021-03-23: +18% vs S&P +8%ALTO 2021-05-20: -18% vs S&P +6%AUB 2024-06-10: +22% vs S&P +1%TBLD 2022-01-05: -7% vs S&P -3%CLX 2025-11-24: +18% vs S&P +3%CMG 2021-04-27: +23% vs S&P +6%CRC 2021-12-22: +8% vs S&P -4%ALSN 2025-08-25: -4% vs S&P +3%AMG 2023-03-17: +13% vs S&P +13%C 2020-10-16: +62% vs S&P +9%RBB 2024-03-18: +2% vs S&P +6%AXP 2025-03-11: +18% vs S&P +8%MRNA 2020-02-18: +323% vs S&P -12%CCOI 2022-11-15: +19% vs S&P +4%CVS 2020-05-13: +8% vs S&P +19%AAP 2023-09-14: +3% vs S&P +5%AMSF 2021-08-26: +7% vs S&P +6%BA 2026-05-22: -2% vs S&P +3%CRM 2025-09-10: +8% vs S&P +5%CNNE 2020-03-13: +16% vs S&P +12%AAON 2025-12-15: +9% vs S&P -2%CODI 2022-05-16: +9% vs S&P +7%BSM 2024-08-15: +7% vs S&P +8%BAC 2023-11-03: +19% vs S&P +13%WWD 2021-08-04: +6% vs S&P +6%BTT 2022-01-25: -9% vs S&P -1%CMCL 2026-08-17: -10% vs S&P -2%CKX 2022-09-06: -3% vs S&P +3%AUNA 2026-06-01: +14% vs S&P +2%BPRN 2025-02-12: +6% vs S&P -2%AMH 2022-11-23: +3% vs S&P -0%AUBN 2020-03-12: +34% vs S&P +29%ARCC 2023-05-04: +13% vs S&P +12%GBLI 2021-11-16: +0% vs S&P -6%CRMD 2025-10-27: -34% vs S&P +1%COP 2025-06-17: -3% vs S&P +11%CBSH 2022-07-28: -0% vs S&P -6%AMT 2026-03-12: +8% vs S&P +9%RBB 2022-05-02: +6% vs S&P -0%BKGM 2020-03-09: -10% vs S&P +17%AESI 2025-02-28: -35% vs S&P -0%BWB 2020-09-03: +21% vs S&P +7%BRK-A 2022-07-07: +0% vs S&P -3%ASMB 2024-11-26: -17% vs S&P -0%ARDX 2025-02-26: -22% vs S&P -0%ATR 2022-11-03: +24% vs S&P +11%BG 2026-08-04: -11% vs S&P -2%AN 2022-05-23: +17% vs S&P +7%CHD 2021-03-04: +10% vs S&P +12%BL 2025-08-11: +12% vs S&P +6%CNO 2023-05-19: +7% vs S&P +5%APO 2022-08-31: +19% vs S&P +0%ADI 2022-06-21: +1% vs S&P +4%AMD 2025-05-22: +49% vs S&P +10%AZO 2022-03-21: +3% vs S&P -17%AMT 2025-11-04: -3% vs S&P +3%CRM 2025-03-03: -9% vs S&P +1%CLVT 2025-08-05: -4% vs S&P +9%AYI 2026-04-10: +20% vs S&P +11%ASYS 2022-05-17: +13% vs S&P +5%AIR 2021-07-29: -6% vs S&P +3%BST 2022-02-04: -14% vs S&P -7%BCAT 2021-11-24: -12% vs S&P -8%OPBK 2022-11-08: +6% vs S&P +8%CWH 2022-05-19: +22% vs S&P +10%BUSE 2025-03-12: +8% vs S&P +8%ASPI 2024-07-10: -19% vs S&P +2%BRCC 2025-08-11: -15% vs S&P +6%CLVT 2021-06-15: -5% vs S&P +6%CRSR 2021-04-09: -7% vs S&P +5%CLX 2025-05-09: -6% vs S&P +12%ACNB 2021-07-01: -2% vs S&P +1%BAH 2024-11-25: -23% vs S&P +1%ARKR 2022-06-28: +2% vs S&P -4%AHCO 2021-03-18: -24% vs S&P +8%CME 2022-12-05: +6% vs S&P +2%CLNN 2022-03-30: -24% vs S&P -17%CCI 2020-12-14: +3% vs S&P +9%LEU 2023-03-17: +7% vs S&P +13%CMI 2025-05-16: +22% vs S&P +9%BHR 2022-05-18: +1% vs S&P +10%BRCC 2025-11-19: -43% vs S&P +3%MEGI 2025-01-06: +3% vs S&P -15%ARDX 2025-01-22: -5% vs S&P -13%CRK 2022-08-08: +24% vs S&P -8%BH 2026-06-05: +31% vs S&P +5%XMTR 2024-05-31: +32% vs S&P +6%CMTG 2022-08-18: -1% vs S&P -7%BHVN 2023-08-31: +76% vs S&P +1%DAL 2023-04-27: +40% vs S&P +11%AOSL 2026-03-10: +120% vs S&P +9%CRT 2026-06-26: +38% vs S&P +6%GBCI 2021-07-29: +3% vs S&P +3%COP 2025-11-10: +23% vs S&P +2%BKNG 2022-08-09: -6% vs S&P -7%ASTC 2022-09-07: -23% vs S&P -1%ASPU 2021-10-04: -59% vs S&P +11%CMG 2022-05-20: +32% vs S&P +10%AGO 2022-08-09: +12% vs S&P -7%JKHY 2023-05-30: +7% vs S&P +6%BSTZ 2025-03-14: +9% vs S&P +8%CTOS 2023-05-16: +3% vs S&P +10%BALL 2022-12-07: +5% vs S&P +2%AAACX 2020-07-28: -1% vs S&P +6%CORT 2020-09-01: +81% vs S&P +3%BV 2026-08-06: +10% vs S&P +0%AEYE 2025-11-24: -42% vs S&P +3%ADC 2026-06-08: +0% vs S&P +4%ADBE 2025-01-30: -16% vs S&P -8%ALIT 2021-12-10: -13% vs S&P -9%ADSK 2026-05-29: +17% vs S&P +2%BRC 2022-03-16: +2% vs S&P -14%DAL 2021-12-01: +12% vs S&P -4%AGEN 2024-02-15: -17% vs S&P +6%ALIT 2025-05-20: -31% vs S&P +9%ARDX 2024-11-14: +16% vs S&P +2%ALIT 2022-03-15: -20% vs S&P -12%AWK 2023-11-06: -3% vs S&P +14%ADC 2025-06-13: -0% vs S&P +10%CMTV 2024-08-05: +7% vs S&P +11%OSG 2020-07-13: +1% vs S&P +11%FBK 2023-06-09: -3% vs S&P +4%CCI 2022-02-24: +16% vs S&P -7%ARTV 2026-07-31: -58% vs S&P +3%CBNA 2025-03-03: +12% vs S&P +1%FBK 2025-02-14: -11% vs S&P -3%APTV 2025-12-16: -8% vs S&P -1%CBOE 2020-11-05: +15% vs S&P +9%BAX 2020-04-01: +10% vs S&P +26%ONEW 2023-02-23: -3% vs S&P +3%CSX 2022-05-16: +4% vs S&P +7%ACR 2023-01-04: +8% vs S&P +7%THG 2021-11-30: +15% vs S&P -4%AMG 2026-05-06: +25% vs S&P +5%AXR 2023-10-13: +31% vs S&P +11%BX 2022-03-01: -1% vs S&P -3%AMPY 2023-03-15: +1% vs S&P +13%AES 2021-09-16: -0% vs S&P +6%CFR 2020-02-10: -25% vs S&P -12%BWFG 2023-03-23: -0% vs S&P +11%BOTJ 2021-08-23: +14% vs S&P +5%CARG 2026-03-04: -15% vs S&P +11%BDX 2025-02-10: -27% vs S&P -6%LMND 2026-03-30: +0% vs S&P +16%CRSP 2025-02-28: -16% vs S&P -0%LMNR 2021-09-28: +4% vs S&P +10%BRCC 2023-12-12: +15% vs S&P +11%AGL 2026-03-03: +553% vs S&P +12%BMBL 2022-03-18: +2% vs S&P -18%BX 2022-05-25: -7% vs S&P +4%ACR 2022-09-06: +1% vs S&P +3%BWFG 2022-06-28: -5% vs S&P -4%ARDC 2022-01-27: -8% vs S&P -3%MED 2021-11-10: -11% vs S&P -2%CAG 2023-10-10: +6% vs S&P +10%CAG 2021-07-16: -2% vs S&P +3%CRL 2023-02-24: -11% vs S&P +5%MEGI 2024-03-20: +2% vs S&P +5%C 2020-09-04: +9% vs S&P +7%AOS 2022-02-22: -16% vs S&P -7%BCO 2022-06-14: +1% vs S&P +10%This buy: result due Feb 18, 2027
Median vs. S&P 500+0.0%
Average vs. S&P 500+5.4%
Best+552.8%
Worst-59.3%

History, not a prediction: what happened next in similar past cases, measured from the day the last filing became public. Not investment advice.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

ELV insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q1 2026: $870K bought (1 trades)$870KQ1 2026: $918K sold (2 trades)Q1 2026Q2 2026: $827K sold (3 trades)Q2 2026Q3 2026: $1.4M bought (3 trades)$1.4MQ3 2026Q4 2026: $384K bought (1 trades)$384KQ4 2026: $5.2M sold (14 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026$384K1$5.2M14
Q3 2026$1.4M3—0
Q2 2026—0$827K3
Q1 2026$870K1$918K2
P/E (trailing)14.9Sector median 25.0
Volume vs. 50-day1.1×Last 5 sessions
Insiders' paper profit+$400KOn all tracked purchases +15.3%

Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 3 Elevance Health insiders reported open-market purchases totaling $2.6M, while 6 insiders reported sales totaling $7.0M. Among insiders with enough purchase history to measure, Steven H. Collis (Director) has the highest Insider Score at 54. 0 of 19 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

ELV earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Oct 21, 2026 +11.6% None +1.2%S&P -0.7% pending
Jul 15, 2026 +10.0% None -12.6%S&P -0.1% +7.4%
Apr 22, 2026 +8.4% None +5.5%S&P +0.6% +14.0%
Jan 28, 2026 -13.9% None +7.5%S&P -0.2% -7.8%
Oct 21, 2025 +1.0% None -2.5%S&P -0.5% -6.8%
Jul 17, 2025 -12.9% None -19.6%S&P +0.5% +11.7%
Apr 22, 2025 -5.2% None +5.0%S&P +4.2% -12.8%
Apr 17, 2025 +0.5% None -6.5%S&P -2.2% -1.6%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

ELV short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-26: 43% of volume sold short2026-08-27: 51% of volume sold short2026-08-28: 64% of volume sold short2026-08-31: 63% of volume sold short2026-09-01: 66% of volume sold short2026-09-02: 57% of volume sold short2026-09-03: 71% of volume sold short2026-09-04: 76% of volume sold short2026-09-08: 63% of volume sold short2026-09-09: 73% of volume sold short2026-09-10: 56% of volume sold short2026-09-11: 65% of volume sold short2026-09-14: 46% of volume sold short2026-09-15: 66% of volume sold short2026-09-16: 56% of volume sold short2026-09-17: 41% of volume sold short2026-09-18: 51% of volume sold short2026-09-21: 63% of volume sold short2026-09-22: 46% of volume sold short2026-09-23: 37% of volume sold short2026-09-24: 45% of volume sold short2026-09-25: 45% of volume sold short2026-09-28: 49% of volume sold short2026-09-29: 52% of volume sold short2026-09-30: 49% of volume sold short2026-10-01: 55% of volume sold short2026-10-02: 44% of volume sold short2026-10-05: 76% of volume sold short2026-10-06: 58% of volume sold short2026-10-07: 58% of volume sold short2026-10-08: 59% of volume sold short2026-10-09: 39% of volume sold short2026-10-12: 60% of volume sold short2026-10-13: 66% of volume sold short2026-10-14: 61% of volume sold short2026-10-15: 36% of volume sold short2026-10-16: 46% of volume sold short2026-10-19: 53% of volume sold short2026-10-20: 45% of volume sold short2026-10-21: 46% of volume sold short2026-10-22: 62% of volume sold short2026-10-23: 51% of volume sold short2026-10-26: 55% of volume sold short2026-10-27: 30% of volume sold short2026-10-28: 46% of volume sold short2026-10-29: 44% of volume sold short2026-10-30: 40% of volume sold short2026-11-02: 20% of volume sold short2026-11-03: 32% of volume sold short2026-11-04: 47% of volume sold short2026-11-05: 40% of volume sold short2026-11-06: 68% of volume sold short2026-11-09: 40% of volume sold short2026-11-10: 53% of volume sold short2026-11-11: 47% of volume sold short2026-11-12: 49% of volume sold short2026-11-13: 64% of volume sold short2026-11-16: 58% of volume sold short2026-11-17: 59% of volume sold short2026-11-18: 40% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 40%20-day average: 45%Prior 2 months: 53%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Members of Congress who traded ELV

From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.

All Congress trades →
MemberTradeTradedReportedSince trade
Alan ArmstrongSenate Bought $1,001 - $15,000 Mar 27, 2026Jul 21, 2026 +37.7%
Markwayne MullinSenate Bought $15,001 - $50,000 Dec 29, 2025Jan 16, 2026 +13.9%

What happened after ELV insiders bought

Each open-market purchase, measured from the day the filing became public, next to the S&P 500 over the same days. Losses included; "pending" means the days haven't passed yet.

Across all stocks →
FiledInsiderBought7 days30 days90 days
Nov 20, 2026Ramiro G. PeruDirector$384K pendingpendingpending
Jul 17, 2026Ramiro G. PeruDirector$366K +1.2%+1.8% vs S&P+4.6%+0.6% vs S&P+15.3%+11.2% vs S&P
Jul 17, 2026Gail BoudreauxCEO, President$1.0M +1.2%+1.8% vs S&P+4.6%+0.6% vs S&P+15.3%+11.2% vs S&P
Mar 6, 2026Steven H. CollisDirector$870K +1.3%+2.8% vs S&P+5.1%+6.9% vs S&P+42.2%+29.3% vs S&P

Insiders at Elevance Health

InsiderBoughtSoldLast filingPast buys beat S&PScore
Mark KayeCFO — $4.7M Oct 23, 2026 — —
Gail BoudreauxCEO, President $1.0M — Jul 17, 2026 — —
Steven H. CollisDirector $870K — May 15, 2026 0 of 1 54
Ramiro G. PeruDirector $750K — Nov 20, 2026 — —
Charles Morgan Kendrick Jr.President — $911K Mar 9, 2026 — —
Ronald W. PenczekCao & Controller — $766K Jun 15, 2026 — —
Ratnakar LavuEvp & Chief Digital Info Ofr — $572K Nov 6, 2026 — —
Robert L. Dixon Jr.Director — $61K Jun 12, 2026 — —
Amy W. SchulmanDirector — $7K May 15, 2026 — —
Erin M. WesslingGeneral Counsel — — Sep 4, 2026 — —
Ryan R. CraigEvp & Chief Hr Officer — — Sep 4, 2026 — —
Lewis Hay IIIDirector — — May 15, 2026 — —
Ryan M. SchneiderDirector — — May 15, 2026 — —
Susan D. DevoreDirector — — May 15, 2026 — —
Deanna D. Strable-SoethoutDirector — — May 15, 2026 — —
Antonio F. NeriDirector — — May 15, 2026 — —
Bahija JallalDirector — — May 15, 2026 — —
Felicia F. NorwoodEvp &Chief Health Benefits Ofr — — Mar 4, 2026 — —
Peter D. HaytaianEvp & Pres Carelon & Carelonrx — — Mar 4, 2026 — —

Board links: companies that share insiders with ELV

Directors and executives who filed Form 4s for ELV and another company in the last 12 months.

See the map →
  • ALNYAlnylam Pharmaceuticals Amy W. Schulman Director here · Director at ALNY · latest filing Nov 12, 2026
  • BLCOBausch & Lomb Steven H. Collis Director here · Director at BLCO · latest filing May 15, 2026
  • HPEHewlett Packard Enterprise Antonio F. Neri Director here · CEO, President at HPE · latest filing Oct 7, 2026
  • IMCRImmunocore Holdings Bahija Jallal Director here · CEO at IMCR · latest filing May 15, 2026
  • LHXL3Harris Lewis Hay III Director here · Director at LHX · latest filing May 15, 2026
  • PFGPrincipal Financial Group Deanna D. Strable-Soethout Director here · CEO, President at PFG · latest filing Sep 29, 2026
  • SMSM Energy Ramiro G. Peru Director here · Director at SM · latest filing Nov 20, 2026
  • SOLVSolventum Susan D. Devore Director here · Director at SOLV · latest filing May 15, 2026
  • TGTTarget Gail Boudreaux CEO, President here · Director at TGT · latest filing Jul 17, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

ELV stock: common questions

Are Elevance Health insiders buying ELV stock?

In the past 12 months, 3 insiders reported open-market purchases of ELV worth $2.6M. The latest was Director Ramiro G Peru bought $384K of ELV at $383.86.

Are Elevance Health insiders selling ELV stock?

6 insiders reported sales worth $7.0M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is ELV's P/E ratio?

ELV trades at about 14.9 times trailing earnings, compared with a median of 25.0 for the Health Care sector.

What is ELV's 52-week range?

Over the past year ELV has traded between $276.69 and $446.28. It last closed at $391.13 on Nov 19, 2026.